These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27657380)

  • 1. The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.
    Cosenza M; Civallero M; Fiorcari S; Pozzi S; Marcheselli L; Bari A; Ferri P; Sacchi S
    Cancer Biol Ther; 2016 Oct; 17(10):1094-1106. PubMed ID: 27657380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
    Cosenza M; Civallero M; Pozzi S; Marcheselli L; Bari A; Sacchi S
    Hematol Oncol; 2015 Dec; 33(4):166-75. PubMed ID: 25394177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
    Bahr JC; Robey RW; Luchenko V; Basseville A; Chakraborty AR; Kozlowski H; Pauly GT; Patel P; Schneider JP; Gottesman MM; Bates SE
    Oncotarget; 2016 Oct; 7(43):69804-69815. PubMed ID: 27634878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.
    Makena MR; Koneru B; Nguyen TH; Kang MH; Reynolds CP
    Mol Cancer Ther; 2017 Apr; 16(4):649-661. PubMed ID: 28119491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
    Mehta-Shah N; Lunning MA; Moskowitz AJ; Boruchov AM; Ruan J; Lynch P; Hamlin PA; Leonard J; Matasar MJ; Myskowski PL; Marzouk E; Nair S; Sholklapper T; Minnal V; Palomba ML; Vredenburgh J; Kumar A; Noy A; Straus DJ; Zelenetz AD; Schoder H; Rademaker J; Schaffer W; Galasso N; Ganesan N; Horwitz SM
    Am J Hematol; 2021 Oct; 96(10):1211-1222. PubMed ID: 34251048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
    Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
    Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells.
    Sun WJ; Huang H; He B; Hu DH; Li PH; Yu YJ; Zhou XH; Lv Z; Zhou L; Hu TY; Yao ZC; Lu MD; Shen X; Zheng ZQ
    Biochem Pharmacol; 2017 Mar; 127():90-100. PubMed ID: 28012958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
    Cortes JR; Patrone CC; Quinn SA; Gu Y; Sanchez-Martin M; Mackey A; Cooke AJ; Shih BB; Laurent AP; Trager MH; Ferrando AA; Geskin LJ; Palomero T
    J Invest Dermatol; 2021 Dec; 141(12):2908-2920.e7. PubMed ID: 34089720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
    Shin DY; Kim A; Kang HJ; Park S; Kim DW; Lee SS
    Cancer Lett; 2015 Aug; 364(2):89-97. PubMed ID: 25790907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
    Chakraborty AR; Robey RW; Luchenko VL; Zhan Z; Piekarz RL; Gillet JP; Kossenkov AV; Wilkerson J; Showe LC; Gottesman MM; Collie NL; Bates SE
    Blood; 2013 May; 121(20):4115-25. PubMed ID: 23532732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
    Karthik S; Sankar R; Varunkumar K; Anusha C; Ravikumar V
    Biomed Pharmacother; 2015 Feb; 69():337-44. PubMed ID: 25661379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
    Patel RP; Thomas JR; Curt KM; Fitzsimmons CM; Batista PJ; Bates SE; Gottesman MM; Robey RW
    Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):16. PubMed ID: 34533562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen enhances romidepsin-induced apoptosis in T-cell malignant cells via activation of FOXO1 signaling pathway.
    Wanitpongpun C; Honma Y; Okada T; Suzuki R; Takeshi U; Suzumiya J
    Leuk Lymphoma; 2021 Jul; 62(7):1585-1596. PubMed ID: 33508992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chidamide-Induced Accumulation of Reactive Oxygen Species Increases Lenalidomide Sensitivity Against Multiple Myeloma Cells.
    Jiang D; Zhang K; Zhu Y; Zhu Y; Zou L; Hu J; Cui Y; Zhou W; Chen F; He Y
    Onco Targets Ther; 2021; 14():4061-4075. PubMed ID: 34262292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
    Vinodhkumar R; Song YS; Devaki T
    Biomed Pharmacother; 2008 Feb; 62(2):85-93. PubMed ID: 17644301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
    Panicker J; Li Z; McMahon C; Sizer C; Steadman K; Piekarz R; Bates SE; Thiele CJ
    Cell Cycle; 2010 May; 9(9):1830-8. PubMed ID: 20404560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romidepsin induces caspase-dependent cell death in human neuroblastoma cells.
    Hegarty SV; Togher KL; O'Leary E; Solger F; Sullivan AM; O'Keeffe GW
    Neurosci Lett; 2017 Jul; 653():12-18. PubMed ID: 28506690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.